National Wealth Management Group LLC Purchases Shares of 3,349 IQVIA Holdings Inc. $IQV

National Wealth Management Group LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 3,349 shares of the medical research company’s stock, valued at approximately $755,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Claret Asset Management Corp grew its stake in IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the period. Versant Capital Management Inc lifted its stake in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after buying an additional 53 shares during the period. Private Advisor Group LLC boosted its holdings in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares in the last quarter. CVA Family Office LLC grew its position in shares of IQVIA by 11.6% during the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after buying an additional 68 shares during the period. Finally, Huntington National Bank increased its stake in shares of IQVIA by 7.8% in the 3rd quarter. Huntington National Bank now owns 969 shares of the medical research company’s stock valued at $184,000 after acquiring an additional 70 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on IQV. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th. Truist Financial reduced their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $229.13.

IQVIA Stock Down 0.3%

Shares of NYSE IQV opened at $165.54 on Thursday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a market capitalization of $28.09 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.60 and a beta of 1.39. The company has a 50-day moving average price of $189.63 and a 200-day moving average price of $205.63.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.